Edgar Filing: NOVAVAX INC - Form 4

NOVAVAX INC									
Form 4 March 17, 2016									
FORM 4									PPROVAL
CURIVI 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								Nome Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								January 31, 2005 average urs per . 0.5
obligations may continue. <i>See</i> Instruction 1(b).	Section 17(a) of the H	Public U	tility Hol	ding Con		nge Act of 1934, of 1935 or Sectio 940	on	
(Print or Type Respon	nses)								
1. Name and Address of Reporting Person <u>*</u> EVANS GARY C			Symbol	r Name an		-	5. Relationship of Reporting Person(s) to Issuer		
			NOVA	VAX INO	C [NVAX	[]	(Check all applicable)		
(Last) (First) (Middle) C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD				f Earliest T Day/Year) 2016	ransaction		X_ Director 10% Owner Officer (give title Other (specify below) below)		
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					1	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
GAITHERSBUR	RG, MD 208	78					Person	More than One R	eporting
(City) ((State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
	ansaction Date th/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securiti nAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	Amount	(D) Price	(Instr. 3 and 4)		
Reminder: Report on	a separate line	for each cla	ass of secu	urities bene	-	-	-		
					inform requir	nation cont ed to resp ys a curre	spond to the colle ained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: NOVAVAX INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day	y/Year)	(Instr.	8)	Acquired or Dispose (D) (Instr. 3, 4 and 5)	ed of				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (Right to buy)	\$ 4.99	03/15/2016		A		40,000		09/15/2016 <u>(1)</u>	03/15/2026	Common Stock	40,000

Reporting Owners

Reporting Owner Name / Address	Relationships								
	Director	10% Owner	Officer	Other					
EVANS GARY C C/O NOVAVAX, INC. 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878	Х								
Signatures									
/s/ John A. Herrmann III, Attorney-in-Fact		03/17	//2016						

**Signature of Reporting Person Explanation of Responses:

through the vesting date.

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") 2015 Stock Incentive (1) Plan will vest six (6) months from the March 15, 2016 grant date subject to continued service on the Company's Board of Directors

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.